 "Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more")
World Bank slashes India's economic growth forecast to 6.5% for FY23
The World Bank on Thursday slashed its growth estimate for India by one percentage point to 6.5 per cent for FY23, citing the blowback of the Russia-Ukraine war and ongoing global monetary policy tightening. Read More
Sebi cancels certificate of registration granted to Brickwork Ratings
Sebi on Thursday cancelled the recognition certificate granted to Brickwork Ratings India, one of the seven registered credit rating agencies (CRAs) in the country, for “repeated lapses” and irregularities in “discharging its duties”. Read More
Also Read
Finance Ministry cuts August 2022 spend: Efficiency or compression?
Even as the Centre faces a much higher spending burden than it did last year, especially on food and fertiliser subsidies, the Union Ministry of Finance’s Expenditure Department seems to have held back spending in August. Read More
Relief for directors of retail firms as govt amends Legal Metrology rules
In a major relief to board members of retail companies and manufacturers of packaged goods, the government has amended the Legal Metrology (General) Rules, 2011, removing the mandatory clause of holding its nominated directors accountable for any violation under the rules. Read More
Maiden Pharma's cough syrups, under WHO scanner, not sold in India: Sources
Delhi-based Maiden Pharmaceuticals, whose cough syrups have come under the scanner of the World Health Organization and the Indian regulator for contamination and linked to the deaths of 66 children in the West African country of Gambia, does not market these products in India, trade sources said. Rajiv Singhal, general secretary of the All India Organisation of Chemists & Druggists (AIOCD), said the body had reached out to the company, which stated this. Read More
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%